
Opinion|Videos|April 30, 2025
Clinical Insights Into Treatment Approach for Metastatic HER+ mBC Patient Case
Panelists discuss how they approach treatment sequencing for HER2-positive (HER2+) metastatic breast cancer (mBC) after progression on first-line therapy, including considerations for trastuzumab deruxtecan and the impressive results from the PATINA trial adding CDK4/6 inhibitors to maintenance therapy.
Advertisement
Episodes in this series

Clinical Brief: Emerging Options for HER2+ mBC
Key Themes:
- Efficacy of Second-Line T-DXd: Trastuzumab deruxtecan (T-DXd) is becoming standard in the second-line setting, supported by National Comprehensive Cancer Network guidelines
- PATINA Trial Results: Adding palbociclib to trastuzumab/pertuzumab/AI maintenance therapy significantly improved progression-free survival (PFS) (44 vs 29 months) in hormone receptor (HR)+/HER2+ disease
- Biological Heterogeneity: Recognition that HR+, HER2+ disease differs biologically from HR-negative (HR–) disease
Key Points for Physicians:
- T-DXd is emerging as the preferred second-line therapy for HER2+ mBC
- The PATINA trial data demonstrate significant PFS benefit with the addition of CDK4/6 inhibition to maintenance therapy in HR+/HER2+ disease
- Insurance coverage for palbociclib in this setting remains challenging until formal guideline inclusion
Notable Insights:
- Approximately 50% of triple-positive (ER+/PR+/HER2+) tumors display luminal characteristics, which may influence treatment response
- The 15-month improvement in PFS with palbociclib addition in the PATINA trial was described as “shocking in the most wonderful way”
- DESTINY-Breast03 data showed impressive efficacy of T-DXd, with 76% of patients still on therapy at 12 months vs 34% with T-DM1
Clinical Significance:
The treatment landscape for HER2+ mBC is rapidly evolving, with emerging data supporting differentiated approaches for HR+ vs HR– disease and promising results for novel combination strategies that may further improve outcomes.
Advertisement
Related to this article

Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.

Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.

A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.

Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.

The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.

An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.

Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
iMMagine-1 vs CARTITUDE-1 MAIC Shows Comparable Efficacy, Improved Safety With Anito-Cel in Relapsed/Refractory Multiple Myeloma
3
Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma
4
Dr Kahl on Frontline Strategies for Avoiding Autologous Transplant in MCL
5

